Novo-Nordisk A/S (NVO)
Healthcare
- Headquarters
- United States
- Employees
- 69,500
- Market Cap
- $208.9B
About Novo-Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
SentiSense also tracks daily options readings for Novo-Nordisk A/S: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Novo-Nordisk A/S stock analysis, sentiment tracking, and market intelligence on SentiSense.